Morgan Stanley analyst Vikram Purohit reiterated an Overweight rating and $26.00 price target on Foghorn Therapeutics (NASDAQ: FHTX) after the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE